Drug-Like Small Molecule Inhibitors of Viral Targets
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 4973
Special Issue Editors
Interests: drug-likeness evaluation; ADME/PK; drug discovery
Special Issue Information
Dear Colleagues,
The outbreak of the COVID-19 pandemic has stressed the urgent need to identify antiviral targets and develop therapeutics against emerging viruses, and the recent success of remdesivir, molnupiravir, and paxlovid has reaffirmed small-molecule inhibitors as a critical antiviral strategy. In early small-molecule drug discovery, drug likeness is an important concept used in the screening and selection of lead compounds that have higher probability of success in later development phase. Drug likeness is referred to as properties of compounds that may confer adequate ADME/pharmacokinetics (PKs) and acceptable toxicity profiles to survive throughout clinical trials.
In this Special Issue, we welcome original research articles, short communications, and reviews related to the discovery, synthesis, and optimization of small-molecule inhibitors against valid viral targets of emerging viruses, including but not limited to coronaviruses, flaviviruses, retroviruses, and herpesviruses. We particularly welcome papers involving studies, either in part or in whole, that seek to evaluate and optimize drug likeness of lead compounds using Lipinski's rule of five, in silico or in vitro ADMET prediction and profiling, multiparameter optimization approaches, PK/PD modeling, or physiologically based PK (PBPK). We also encourage the submission of papers related to new antiviral targets, new antiviral drug combinations, or drug repurposing.
We look forward to receiving your submissions!
Dr. Jiashu Xie
Dr. Yan Wang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- emerging viruses
- small-molecule inhibitors
- antiviral
- drug likeness
- viral targets
- drug discovery
- ADME
- PK
- toxicity
- drug combination
- drug repurposing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
